BRAF and non-small cell lung carcinoma: Additionally, Dabrafenib plus Trametinib is suggested for patients with advanced NSCLC and positive BRAF V600 mutations.48 The utilization of immune checkpoint inhibitors (ICIs) in advanced LUAD can prolong survival for select lung cancer patients, offering an innovative and effective treatment.49 Regarding gene mutation analysis, high SGO2 clusters exhibit a higher tumor mutational burden (TMB) compared to low SGO2 clusters.